These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3932153)

  • 1. [Agnogenic myeloid metaplasia and polycythemia vera in the same family].
    Tosato F; Pirrone S; Manzo M; Diplotti L; Sponza E
    Haematologica; 1985; 70(3):240-1. PubMed ID: 3932153
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-polycythemia myeloid metaplasia: experience with a large cohort of patients.
    Randi ML; Barbone E; Fabris F; Varotto L; Macri C; Girolami A
    J Med; 1994; 25(6):363-9. PubMed ID: 7769374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Familial myeloproliferative syndromes. Study of 6 families and review of literature].
    Kaufman S; Brière J; Bernard J
    Nouv Rev Fr Hematol (1978); 1978 Apr; 20(1):1-15. PubMed ID: 353725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic parameters in myeloid metaplasia: agnogenic versus postpolycythemic.
    Meytes D; Katz D; Ramot B
    Isr J Med Sci; 1976 Jun; 12(6):534-42. PubMed ID: 955869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of myeloproliferative diseases.
    Sellei C
    Ther Hung; 1966; 14(4):135-6. PubMed ID: 5228101
    [No Abstract]   [Full Text] [Related]  

  • 7. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome deletion [46,XX,del(20)(q11)] in agnogenic myeloid metaplasia.
    Findley L; Kurnick JE; Peakman DC; Robinson A
    Hum Genet; 1979 Mar; 47(2):207-11. PubMed ID: 437786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Postpolycythemic myeloid metaplasia in patients with polycythemia vera].
    Spasojević J; Pejin D; Stajnic S
    Med Pregl; 1997; 50(5-6):224-8. PubMed ID: 9297056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of polycythemia vera with busulfan].
    Kratochvil J; Mrkos D
    Vnitr Lek; 1966 Jul; 12(7):673-81. PubMed ID: 5967585
    [No Abstract]   [Full Text] [Related]  

  • 13. Associated cancers in parents and offspring of polycythaemia vera and myelofibrosis patients.
    Hemminki K; Sundquist J; Bermejo JL
    Br J Haematol; 2009 Nov; 147(4):526-30. PubMed ID: 19754924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypocholesterolemia and other lipoprotein disorders in myelofibrosis].
    Kiss A; Telek B; Rák K
    Orv Hetil; 1994 Nov; 135(48):2643-6. PubMed ID: 7808738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy in polycythemia vera.
    Stecher G; Reinhardt G
    Acta Genet Med Gemellol (Roma); 1968 Jan; 17(1):292-302. PubMed ID: 5241850
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary polycythaemia. 3. Studies on the significance of the history of the disease and of the treatment for the development of clones in bone marrow cells.
    Visfeldt J; Franzén S; Nielsen A; Tribukait B
    Acta Pathol Microbiol Scand A; 1973 Mar; 81(2):195-203. PubMed ID: 4734062
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of polycythemia vera in a patient with myeloid metaplasia and myelofibrosis. Report of a case with a comment on its significance in relation to prevailing views on myeloid metaplasia.
    Hershko C; Polliack A
    Isr J Med Sci; 1971 Feb; 7(2):315-20. PubMed ID: 5560987
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapy of polycythemia vera with myleran].
    Krykowski E; Wislawska B; Polkowska-Kulesza E
    Przegl Lek; 1965; 21(7):481-3. PubMed ID: 5848465
    [No Abstract]   [Full Text] [Related]  

  • 19. Busulphan and the lungs. Absence of lung function disturbance in patients treated with busulphan.
    Comhaire F; Van Hove W; Van Ganse W; Van der Straeten M
    Scand J Respir Dis; 1972; 53(5):265-73. PubMed ID: 4508954
    [No Abstract]   [Full Text] [Related]  

  • 20. Procarbazine (Natulan) and busulfan in the treatment of polycythemia vera.
    Penttilä O; Ikkala E
    Ann Med Intern Fenn; 1968; 57(2):99-101. PubMed ID: 5706392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.